Imunon Inc (IMNN)

Currency in USD
6.4000
-0.2000(-3.03%)
Closed·
6.40000.0000(0.00%)
·
IMNN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
IMNN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.40006.7500
52 wk Range
4.826141.2174
Key Statistics
Prev. Close
6.6
Open
6.45
Day's Range
6.4-6.75
52 wk Range
4.8261-41.2174
Volume
36.36K
Average Volume (3m)
1.02M
1-Year Change
-50.93%
Book Value / Share
1.63
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMNN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
100.5978
Upside
+1,471.84%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Imunon Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Imunon Inc Company Profile

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Imunon Inc Earnings Call Summary for Q2/2025

  • Imunon reported Q2 2025 EPS of -$2.15, missing forecasts of -$0.32; stock fell 10% in total
  • Net loss improved to $2.7M from $4.8M YoY; R&D and G&A expenses reduced significantly
  • Company advancing OVATION III Phase 3 trial for ovarian cancer; aims to expand to 20 clinical sites by year-end
  • Pursuing strategic financing to regain NASDAQ compliance; exploring non-dilutive options and partnerships
  • FY 2025 and 2026 EPS forecasts at -$14.77 and -$23.17 respectively; CEO acknowledges challenging capital markets
Last Updated: 05/08/2025, 19:38
Read Full Transcript

Compare IMNN to Peers and Sector

Metrics to compare
IMNN
Peers
Sector
Relationship
P/E Ratio
−1.0x−4.8x−0.5x
PEG Ratio
−0.02−0.120.00
Price/Book
6.1x−1.5x2.6x
Price / LTM Sales
-152.2x3.3x
Upside (Analyst Target)
-309.8%40.3%
Fair Value Upside
Unlock−3.4%5.1%Unlock

Analyst Ratings

3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 100.5978
(+1,471.84% Upside)

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
-2.15 / -0.32
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

IMNN Income Statement

People Also Watch

57.81
BMNR
-4.37%
21.81
SRPT
+7.44%
3.170
OPEN
+4.28%
2.140
VOR
+8.08%
0.0544
WLGS
-6.37%

FAQ

What Stock Exchange Does Imunon Trade On?

Imunon is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Imunon?

The stock symbol for Imunon is "IMNN."

What Is the Imunon Market Cap?

As of today, Imunon market cap is 16.14M.

What Is Imunon's Earnings Per Share (TTM)?

The Imunon EPS (TTM) is -13.47.

When Is the Next Imunon Earnings Date?

Imunon will release its next earnings report on 16 Nov 2025.

From a Technical Analysis Perspective, Is IMNN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Imunon Stock Split?

Imunon has split 5 times.

How Many Employees Does Imunon Have?

Imunon has 25 employees.

What is the current trading status of Imunon (IMNN)?

As of 16 Aug 2025, Imunon (IMNN) is trading at a price of 6.40, with a previous close of 6.60. The stock has fluctuated within a day range of 6.40 to 6.75, while its 52-week range spans from 4.83 to 41.22.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.